Michael Crowther

Researcher based in Copenhagen working on Cancer Immunotherapy

[Michael Crowther @Michael44364760]

More info on my research that has just been published in Nature Immunology!

[Cardiff University @cardiffuni]

A new type of immune cell which kills most cancers has been discovered by #CardiffUni scientists, offering fresh hope of universal treatment for all patients.

Find out more 👉 https://t.co/PAsZTOV8nc

[Michael Crowther @Michael44364760]

Was a pleasure to contribute, congrats on the great work @TcellResearch Sewell lab!

[CCIT-DK: National Center for Cancer Immune Therapy @CCITdk]

Cross-reactive tumor-infiltrating lymphocytes #TILs
on @CellCellPress
🎯 Targeting multiple tumor-associated antigens by individual T cell receptors during successful #cancer #Immunotherapy

👉 https://t.co/tNWKPq2WVz

🇩🇰 @Michael44364760, @DoniaMarco, Inge Marie Svane + 🏴󠁧󠁢󠁷󠁬󠁳󠁿

[Marco Donia @DoniaMarco]

🌟 Did you know CD4+ T cells can kill #immunotherapy-resistant #cancer?
👉 https://t.co/mPj9S5npwN published by
@CCR_AACR

🎯 We revealed a new approach that may overcome some immune checkpoint blockade (ICB)-resistant tumors by harnessing CD4+ T cells

#TILs #Melanoma

[Michael Crowther @Michael44364760]

@TcellResearch I remember helping to make that poster many years ago!

[T-cell Modulation Group @TcellResearch]

We’re currently advertising for a lab manager position in the group - see the link if you’re interested! 🥼 #immunology #tcells #labmanager

https://t.co/A0MoXUBij2

[Michael Crowther @Michael44364760]

@pagh_nikolaj @sunny0744 @JL_Reading @marcus_buggert Congrats Nikolaj 😀

[Michael Crowther @Michael44364760]

If you would like to discover more about how to de-orphanise T-cells using whole genome CRISPR-cas9, @MatLegut, @TcellResearch and I wrote a method chapter for the book on 'T-Cell Repertoire Characterization', published in Methods in Molecular Biology.
https://t.co/acqgVhDYeF

[Michael Crowther @Michael44364760]

Happy to share a new paper from the @DoniaMarco group, was a pleasure being a part of a really interesting study!
We show how melanoma under immune selection undergoes genetic changes to escape recognition.

[Cancer Immunology Research @CIR_AACR]

Check out how #melanoma acquires resistance to multiple lines of #immunotherapy by gaining consecutive alterations, resulting in pan T-cell immune escape. By Nielsen, @MarioPre_, Svane, @DoniaMarco et al.
https://t.co/Ww9FZlzRew
@AriannaDraghi @CAChamberlain_ @Michael44364760

[CCIT-DK: National Center for Cancer Immune Therapy @CCITdk]

Patients' own immune cells can be transformed into a potent #immunotherapy for #melanoma, an aggressive type of skin #cancer.

The M14TIL trial, the first phase 3 study of T cell therapy in solid tumors, was just presented at #ESMO22 @myESMO. Full news at https://t.co/p1z11q7MLI

[CCIT-DK: National Center for Cancer Immune Therapy @CCITdk]

8+ years purely academic effort of @CCITdk and @NKI_nl bringing fruits for patients with #melanoma and for science at #ESMO22 . Congrats to @HaanenJohn and Inge Marie Svane's teams! @myESMO

[Morten Orebo Holmström @holmstrom_mo]

Enjoying well deserved coffee and cake after the first common lab cleaning at @CCITdk. We now have our own lab! 🤟🥳🔬🧬🧫 Thanks to @MortenCCIT for organizing.
With @thomas_hulen, @Michael44364760, @AriannaDraghi, @DanielHMadsen and others.

[Michael Crowther @Michael44364760]

Amazing work Mat, big congratulations!!!!

[Mat Legut, PhD @MatLegut]

Really chuffed to share our latest work from Sanjana Lab out in @nature today (https://t.co/skHTGrKACw).

We tested >12,000 genes to find positive regulators of T cell proliferation to be used for next-gen #immunotherapies.

A thread...

[Molecular Therapy Family of Journals @MolTherapy]

Researchers at @HerlevGentofte reported on highly efficient PD-1-targeted #CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T #celltherapy in @moltherapy Oncolytics (#MTO). https://t.co/CVVzUKEhPw

[Michael Crowther @Michael44364760]

@pagh_nikolaj @CCITdk @DTU_HealthTech Congrats Nikolaj :)

[Journal of Clinical Investigation @jclinicalinvest]

#ClinicalMedicine: Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma: https://t.co/OZNHUcjzHe
@ccitdk @DTUtweet @DTU_HealthTech
#Immunology #Therapeutics

[Marco C. @mark_wagon]

Fresh off the press: Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment @CCITdk
https://t.co/Y12GFkUeiJ

[CCIT-DK: National Center for Cancer Immune Therapy @CCITdk]

Big day for @CCITdk! Basic discoveries from @CCITdk developed into a clinical trial at @CCITdk. Anti-PD1 #immunotherapy plus #vaccine against IDO/PD-L1, impressive response rates. Hope for more effective treatments for patients with #Melanoma #melsm #dkforsk

[Morten Orebo Holmström @holmstrom_mo]

Today at @CCITdk learning to perform #scRNASeq using the #10x Chromium platform together with @Michael44364760, Marie Westergaard and @thomas_hulen.

[Michael Crowther @Michael44364760]

Was great to help out in this paper! Congrats to Nikolaj, Christina, Siri and Sine Reker on getting it published!

[JonssonMelanomaLab @jonsson_lab]

Happy to play a small part in this study! Great work not on twitter Sine Hadrups group @DTUtweet and @CCITdk !
JCI - Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive transfer with tumor-infiltrating lymphocytes in melanoma https://t.co/2Emp6ZSZ5R
#melanoma

[Kasper Mølgaard @kasperMoelgaard]

Happy to have contributed to this novel study showing that #DHODH inhibition impairs #TCell proliferation but not synthesis of effector molecules due to reduced levels of pyrimidines. Study by Marlies P. out December in @FrontImmunol 🎉 https://t.co/XSTO2AJ7Vu

[Frontiers - Immunology @FrontImmunol]

New Research: Rapid Identification of the Tumor-Specific Reactive TIL Repertoire via Combined Detection of CD137, TNF, and IFNγ, Following Recognition of Autologous Tumor-Antigens: Detecting the entire repertoire of tumor-specific reactive… https://t.co/Hrm5MoI2ik #immunology